Join Now

Category Archives: BioUtah News

PDV MedTech and Corscience Announce Strategic Partnership to Advance MedTech Development and Manufacturing Across the US and Europe

By Natalie Themm | Published July 9, 2026

Collaboration connects European development expertise with U.S. manufacturing to give medtech innovators a seamless path from concept to commercialization for safety-critical medical devices.

| Tagged | Comments Off on PDV MedTech and Corscience Announce Strategic Partnership to Advance MedTech Development and Manufacturing Across the US and Europe

Nomi Health CEO Mark Newman Testifies Before U.S. House on Direct Contracting

By Natalie Themm | Published July 1, 2026

Newman presents evidence that direct contracting can lower healthcare costs, improve transparency, and return savings to workers.

| Tagged | Comments Off on Nomi Health CEO Mark Newman Testifies Before U.S. House on Direct Contracting

Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test

By Natalie Themm | Published July 1, 2026

More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs.

| Tagged | Comments Off on Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test

Cytiva Completes Doubling of Utah Site’s Liquid Media Production Capacity

By Natalie Themm | Published July 1, 2026

Project designed to support supply chain continuity for customers relying on the company for their cell culture needs.

| Tagged | Comments Off on Cytiva Completes Doubling of Utah Site’s Liquid Media Production Capacity

bioMérieux Seeks FDA Clearance for Updated Gastrointestinal Testing Panels

By Natalie Themm | Published July 1, 2026

The new molecular panels are designed to detect up to 22 pathogens in one hour with enhanced norovirus detection.

| Tagged | Comments Off on bioMérieux Seeks FDA Clearance for Updated Gastrointestinal Testing Panels

M42’s IROS launches UAE’s first genomics-driven clinical trial to prevent Alzheimer’s disease

By Natalie Themm | Published July 1, 2026

Alzheimer’s disease is one of the world’s most pressing health challenges, affecting more than 55 million people globally; a number expected to nearly triple by 2050.

| Tagged , | Comments Off on M42’s IROS launches UAE’s first genomics-driven clinical trial to prevent Alzheimer’s disease

Ratio Therapeutics Enters Strategic Actinium-225 Supply Agreement with PanTera to Support Radiopharmaceutical Development Programs

By Natalie Themm | Published July 1, 2026

Collaboration strengthens Ratio’s long-term isotope supply strategy for clinical development and future pipeline growth.

| Tagged | Comments Off on Ratio Therapeutics Enters Strategic Actinium-225 Supply Agreement with PanTera to Support Radiopharmaceutical Development Programs

PolarityBio Announces Submission of its Biologics License Application for SkinTE® for the Treatment of Wagner Grade 1 Diabetic Foot Ulcers

By Natalie Themm | Published July 1, 2026

SkinTE® would be the first new biologic commercially available in the U.S. for the treatment of a common chronic wound indication in nearly 30 years, if approved.

| Tagged | Comments Off on PolarityBio Announces Submission of its Biologics License Application for SkinTE® for the Treatment of Wagner Grade 1 Diabetic Foot Ulcers

KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

By Natalie Themm | Published July 1, 2026

Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk-stratified improvements in kidney function, increases in guideline-directed therapy uptake, and – for the first time – measurable reduction in individual patient risk trajectories over 24 months

| Tagged | Comments Off on KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

FDA Approves Roflumilast Cream 0.3% for Plaque Psoriasis Down to Age 2

By Natalie Themm | Published July 1, 2026

Indication expansion addresses a major pediatric gap where topical corticosteroids are commonly used off-label yet constrained by sensitive-site and long-term continuous-use limitations.

| Tagged | Comments Off on FDA Approves Roflumilast Cream 0.3% for Plaque Psoriasis Down to Age 2

Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications

By Natalie Themm | Published July 1, 2026

Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis.

| Tagged | Comments Off on Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications

Early-Phase Data Support Novel Contrast Agent

By Natalie Themm | Published July 1, 2026

ASE 2026 data support further development of MVT-100 in pivotal trials.

| Tagged | Comments Off on Early-Phase Data Support Novel Contrast Agent

A Special Thanks To Our Legacy and Platinum Elite Members